RITUXAN HYCELA Drug Profile

Summary for Tradename: RITUXAN HYCELA

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for RITUXAN HYCELA

Recent Clinical Trials for RITUXAN HYCELA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Academic and Community Cancer Research United	Phase 2
National Cancer Institute (NCI)	Phase 2
National Cancer Institute (NCI)	Phase 3

See all RITUXAN HYCELA clinical trials

Pharmacology for RITUXAN HYCELA

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody Endoglycosidase
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RITUXAN HYCELA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RITUXAN HYCELA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2034-04-24	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2032-02-22	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2035-11-18	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2039-06-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RITUXAN HYCELA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,004,694	2033-09-12	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,004,745	2036-03-10	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,005,783	2037-01-05	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,016,412	2036-12-09	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	10,016,440	2031-04-21	Patent claims search

International Patents for RITUXAN HYCELA

Country	Patent Number	Estimated Expiration
Japan	2015061839
Eurasian Patent Organization	031972
Japan	5898146
Mexico	2012002861
Israel	208518
South Korea	20100135291

Supplementary Protection Certificates for RITUXAN HYCELA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02475353/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016

Market Dynamics and Financial Trajectory for RITUXAN HYCELA

Last updated: February 19, 2026

What is RITUXAN HYCELA?

RITUXAN HYCELA is a biosimilar combination product developed by Roche, combining rituximab and hyaluronidase. It is designed for subcutaneous administration, primarily intended to treat conditions including non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. Biosimilar versions of rituximab aim to reduce treatment costs and improve administration convenience compared to intravenous formulations.

How does the market landscape look for RITUXAN HYCELA?

Competitive Position

RITUXAN HYCELA entered a mature biologic market dominated by the originator Rituxan (distributed by Genentech/Roche), which has annual sales of approximately $7 billion globally (2022). Biosimilars for rituximab have been approved or launched in key markets including the US, EU, and Japan, intensifying competition.

Key Players

Product Name	Producer	Approval Year	Formulation	Market Focus
RITUXAN	Roche/Genentech	1997	IV	Oncology, autoimmune diseases
RUXIENCE	Biogen/Celltrion	2019	SC (subcutaneous)	Oncology
TRUXIMA	Teva/Celltrion	2018	IV	Oncology
RIABNI	Amgen	2017	IV	Oncology
RITUXAN HYCELA	Roche	2018	SC (subcutaneous)	Oncology, autoimmune diseases

Market Adoption Patterns

The transition to biosimilars in the US remains gradual, slowed by patent litigations, switching costs, and physician preferences. RITUXAN HYCELA benefits from the increasing preference for subcutaneous administration, driven by reduced administration time and lower healthcare resource utilization.

Regulatory Trends

The US Food and Drug Administration (FDA) approved RITUXAN HYCELA in 2018. The European Medicines Agency (EMA) granted approval in the same year. Regulatory approval has generally followed rigorous biosimilar evidence submission, emphasizing analytical similarity, non-clinical, and clinical data.

Pricing and Reimbursement

Biosimilar medication prices typically range 15-30% below the originator. In the US, payer policies increasingly favor biosimilar adoption to contain costs. RITUXAN HYCELA, by offering subcutaneous delivery, has added value in reducing healthcare facility burden, influencing reimbursement policies positively.

What are the projected financial trends?

Revenue Projections

Biosimilar rituximab sales are expected to grow at a compound annual growth rate (CAGR) of approximately 15% from 2023 to 2028 (IQVIA, 2023). RITUXAN HYCELA's contribution hinges on market penetration, which remains limited by factors including physician acceptance and reimbursement policies.

Market Share Estimates

Year	Estimated Market Share of RITUXAN HYCELA	Assumptions
2023	10%	Initial uptake, primarily in US and Europe
2024	15%	Increased physician familiarity; price advantage
2025	20%	Erosion of originator market; broader indications observed

Revenue Calculations

Assuming US and EU combined annual sales of rituximab biosimilars reach $15 billion by 2028, and RITUXAN HYCELA captures approximately 15% of the biosimilar rituximab market, revenues could approach $2.25 billion globally in that year. However, actual sales could vary based on regulatory approvals, market access, and competitive dynamics.

What are the main risk factors impacting RITUXAN HYCELA’s financial trajectory?

Regulatory Delays and Market Access

Delays in approval or reimbursement restrictions could hinder uptake. Countries with slower biosimilar adoption or patent disputes can delay market penetration.

Physician and Patient Acceptance

Clinician preference for intravenous administration or hesitance to switch from innovator products affects adoption rates. The convenience of subcutaneous formulations may offset these barriers.

Competitive Landscape

Emergence of new biosimilars, monoclonal antibody innovations, or alternative therapies (e.g., CAR-T cells) could reduce demand.

Pricing and Reimbursement Policies

Shelf prices and reimbursement policies directly influence revenue. Payers may negotiate deeper discounts to favor biosimilar substitution.

What strategic moves could influence future growth?

• Demonstrating cost savings and clinical equivalence to physicians.
• Expanding indications where subcutaneous delivery offers clear benefits.
• Entering emerging markets with high unmet need.
• Building strong payer relationships for favorable reimbursement terms.

Key Takeaways

• RITUXAN HYCELA occupies a niche driven by convenience and competitive pricing, targeting a mature market with multiple biosimilars.
• Revenue growth will depend on market penetration, regulatory environment, and physician acceptance.
• Biosimilar rituximab sales are projected to grow steadily, with RITUXAN HYCELA potentially capturing a significant share in the subsequent years.
• Price competition and reimbursement policies remain critical factors shaping its financial trajectory.
• Industry shifts towards innovative therapies could limit long-term growth unless RITUXAN HYCELA expands into new indications or markets.

FAQs

1. What differentiates RITUXAN HYCELA from other rituximab biosimilars?

It is a subcutaneous formulation designed to reduce administration time and healthcare resource use, offering a more convenient option compared to intravenous biosimilars.

2. How significant is the market for rituximab biosimilars globally?

The global rituximab biosimilar market reached approximately $4.4 billion in 2022, with expected CAGR of 15% through 2028.

3. Which regions are most favorable for RITUXAN HYCELA expansion?

The US and Europe are primary markets, with emerging markets in Asia and Latin America offering growth opportunities owing to increasing biosimilar acceptance.

4. What are the main barriers for RITUXAN HYCELA’s market share growth?

Physician hesitation to switch to biosimilars, reimbursement uncertainties, and patent litigation are steady barriers.

5. How might new therapeutic modalities impact the rituximab market?

Innovations like CAR-T therapies could replace rituximab in certain indications, limiting growth of existing monoclonal antibody biosimilars.

---

References

[1] IQVIA. (2023). Global Biosimilar Market Report. IQVIA Institute for Human Data Science.

[2] U.S. Food and Drug Administration. (2018). RITUXAN HYCELA approval notice. FDA.

[3] European Medicines Agency. (2018). RITUXAN HYCELA marketing authorization. EMA.